Literature DB >> 17512555

Changes in extracellular activin A:follistatin ratio during differentiation of a mesenchymal progenitor cell line, ROB-C26 into osteoblasts and adipocytes.

Niki Kawabata1, Naoko Kamiya, Naoto Suzuki, Mitsuhiko Matsumoto, Minoru Takagi.   

Abstract

We investigated the effects of BMP-2 and dexamethasone (Dex) on follistatin (FS) and activin A expressions in a mesenchymal progenitor cell line, ROB-C26 (C26). C26 cells stimulated to differentiate into osteoblastic cells by blocking myogenic differentiation after BMP-2 treatment and into adipocytes with Dex treatment. Alkaline phosphatase (ALP) mRNA expression and its activity in the confluent C26 cells were dose- and time-dependently stimulated by BMP-2, but inhibited by Dex. The stimulatory effect on FS and activin A mRNA expressions by BMP-2 and Dex were dose-dependent. Cycloheximide pre-treatment indicated that FS and activin A expressions appear to be the direct target of BMP-2 and Dex signaling. BMP-2 time-dependently increased FS and activin A levels. Dex also increased FS level, but induced a time-dependent biphasic effect on activin A level, a decrease (2-6 h) followed by an increase (12-72 h). The data of the ratio of activin A concentration in the culture media to that of FS (activin A:FS ratio) measured by ELISA showed that BMP-2-induced osteoblastic differentiation involved an activin-dominant microenvironment, whereas Dex-induced adipocyte differentiation involved a FS-dominant microenvironment. Excess FS suppressed the stimulatory ALP activity of BMP-2, whereas activin A prevented not only Dex-induced inhibitory ALP activity, but also adipogenesis via suppression of the adipocyte transcriptional factor cascade. These results indicate that BMP-2-induced activin-dominant microenvironment may be critical for osteoblastic differentiation by restricting the antagonistic effects of FS on BMP activity, while Dex-induced FS-dominant microenvironment may be critical for adipocyte differentiation by restricting the inhibitory action of activin A on adipocyte differentiation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17512555     DOI: 10.1016/j.lfs.2007.04.011

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  8 in total

1.  Serum follistatin in patients with prostate cancer metastatic to the bone.

Authors:  Francesca Maria Tumminello; Giuseppe Badalamenti; Fabio Fulfaro; Lorena Incorvaia; Marilena Crescimanno; Carla Flandina; Maria Vittoria Sepporta; Gaetano Leto
Journal:  Clin Exp Metastasis       Date:  2010-07-11       Impact factor: 5.150

2.  TGF-β regulates sclerostin expression via the ECR5 enhancer.

Authors:  Gabriela G Loots; Hansjoerg Keller; Olivier Leupin; Deepa Murugesh; Nicole M Collette; Damian C Genetos
Journal:  Bone       Date:  2011-12-02       Impact factor: 4.398

3.  Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease.

Authors:  Sonia Vallet; Siddhartha Mukherjee; Nileshwari Vaghela; Teru Hideshima; Mariateresa Fulciniti; Samantha Pozzi; Loredana Santo; Diana Cirstea; Kishan Patel; Aliyah R Sohani; Alex Guimaraes; Wanling Xie; Dharminder Chauhan; Jesse A Schoonmaker; Eyal Attar; Michael Churchill; Edie Weller; Nikhil Munshi; Jasbir S Seehra; Ralph Weissleder; Kenneth C Anderson; David T Scadden; Noopur Raje
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-01       Impact factor: 11.205

Review 4.  Clinical and Therapeutic Implications of Follistatin in Solid Tumours.

Authors:  Lei Shi; Jeyna Resaul; Sioned Owen; Lin Ye; Wen G Jiang
Journal:  Cancer Genomics Proteomics       Date:  2016 11-12       Impact factor: 4.069

5.  BMP-2 Induced Signaling Pathways and Phenotypes: Comparisons Between Senescent and Non-senescent Bone Marrow Mesenchymal Stem Cells.

Authors:  Jae Hwan Cho; Jae Hyup Lee; Kyung Mee Lee; Choon-Ki Lee; Dong-Myung Shin
Journal:  Calcif Tissue Int       Date:  2021-10-29       Impact factor: 4.333

Review 6.  Follistatin as potential therapeutic target in prostate cancer.

Authors:  Maria Vittoria Sepporta; Francesca Maria Tumminello; Carla Flandina; Marilena Crescimanno; Marco Giammanco; Maurizio La Guardia; Danila di Majo; Gaetano Leto
Journal:  Target Oncol       Date:  2013-03-01       Impact factor: 4.493

7.  Activin A expression regulates multipotency of mesenchymal progenitor cells.

Authors:  Farida Djouad; Wesley M Jackson; Brent E Bobick; Sasa Janjanin; Yingjie Song; George T J Huang; Rocky S Tuan
Journal:  Stem Cell Res Ther       Date:  2010-05-04       Impact factor: 6.832

8.  Activin A Promotes Osteoblastic Differentiation of Human Preosteoblasts through the ALK1-Smad1/5/9 Pathway.

Authors:  Hideki Sugii; Mhd Safwan Albougha; Orie Adachi; Hiroka Tomita; Atsushi Tomokiyo; Sayuri Hamano; Daigaku Hasegawa; Shinichiro Yoshida; Tomohiro Itoyama; Hidefumi Maeda
Journal:  Int J Mol Sci       Date:  2021-12-16       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.